RxDoctor Payments Data

Gunther Rencken, MD

Family Medicine · Walterboro, SCNPI 1568402089

Payments from drug & device makers

$784in general payments, 2019–2025

Across 30 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$309
  • AstraZeneca$200
  • Cardiovascular Systems Inc.$94
  • Pfizer$48
  • Novartis$33
  • Ironwood Pharmaceuticals, Inc$32
  • plus $69 from 3 others

What the payments were for

  • Food & beverage$784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$784 in reported general payments places this provider in the 55th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$8,369
Medicare patients
150
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide188$229,882
EliquisApixaban218$202,830
MounjaroTirzepatide145$168,656
FarxigaDapagliflozin Propanediol199$137,120
JanuviaSitagliptin Phosphate148$125,383
Tresiba Flextouch U-100Insulin Degludec78$51,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$50,545
MyrbetriqMirabegron68$50,537
LinzessLinaclotide66$47,336
Tresiba Flextouch U-200Insulin Degludec31$39,928
JardianceEmpagliflozin29$39,416
TrulicityDulaglutide18$28,807
Combivent RespimatIpratropium/Albuterol Sulfate26$23,259
XareltoRivaroxaban12$19,837
Breo ElliptaFluticasone/Vilanterol32$16,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$309$229,882188 claims
PfizerEliquis$48$202,830218 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$200$149,268227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Walterboro

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →